Cutaneous T-Cell Lymphoma: A Paradigm for Biological Therapies

References

• Weinstock, M.A. and Horm, J.W. (1988) "Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiol-ogy", JAMA, 260, 42–46.
   Google Scholar
• Willemze, R., Ken, H., Sterry, W., Berti, E., Cerroni, L., Chimenti, S., et al. (1997) "EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer", Blood, 90, 354–371.
   Google Scholar
• Kim, Y.H., Jensen, R.A., Watanabe, G.L., Varghese, A. and Hoppe, R.T. (1996) "Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis", Archives of Dermatology, 132, 1309 — 1313.
   Google Scholar
• van Doom, R., Dijkman, R., Vermeer, M.H., Starink, T.M., Willemze, R. and Tensen, C.P. (2002) "A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma", Cancer Research, 62, 5389 — 5392.
   Google Scholar
• Zoi-Toli, 0., Vermeer, M.H., De Vries, E., Van Beek, P., Meijer, C.J. and Willemze, R. (2000) "Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL", British Journal of Dermatology, 143, 313–319.
   Google Scholar
• Mao, X., Orchard, G., Lillington, D.M., Russell-Jones, R., Young, B.D. and Whittaker, S.J. (2003) "Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas", Blood, 101, 1513 — 1519.
   Google Scholar
• Qin, J.Z., Dummer, R., Burg, G. and Dobbeling, U. (1999) "Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells", Blood, 93, 260–267.
   Google Scholar
• Drillenburg, P., Bronkhorst, C.M., van der Wal, A.C., Noorduyn, L.A., Hoekzema, R. and Pals, S.T. (1997) "Expression of adhesion molecules in pagetoid reticulosis (Woringer-Kolopp disease)", British Journal of Dermatology, 136, 613–616.
   Google Scholar
• Griffiths, C.E., Voorhees, J.J. and Nickoloff, B.J. (1989) "Char-acterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor", Journal of the American Academy of Dermatology, 20, 617 — 629.
   Google Scholar
• Drillenburg, P. and Pals, S.T. (2000) "Cell adhesion receptors in lymphoma dissemination", Blood, 95, 1900— 1910.
   Google Scholar
• Vowels, B.R., Cassin, M., Vonderheid, E.C. and Rook, A.H. (1992) "Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells", The Journal of Investigative Dermatology, 99, 90–94.
   Google Scholar
• Lee, B.N., Duvic, M., Tang, C.K., Bueso-Ramos, C., Estrov, Z. and Reuben, J.M. (1999) "Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma", Clinical and Diagnostic Laboratory Immunology, 6, 79–84.
   Google Scholar
• Kaye, F.J., Bunn, Jr., P.A., Steinberg, S.M., Stocker, J.L., Ihde, D.C., Fischmann, A.B., et al. (1989) "A randomized trial comparing combination electron-beam radiation and che-motherapy with topical therapy in the initial treatment of mycosis fungoides", New England Journal of Medicine, 321, 1784— 1790.
   Google Scholar
• Reddy, S., Parker, C.M., Shidnia, H., Gaffney, M.G., Blyton, B.D., Pruner, L.M. and Kalasinski, L.A. (1992) "Total skin electron beam radiation therapy for mycosis fungoides", American Journal of Clinical Oncology, 15, 119 — 124.
   Google Scholar
• Kim, Y.H., Martinez, G., Varghese, A. and Hoppe, R.T. (2003) "Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience", Archives of Dermatology, 139, 165–173.
   Google Scholar
• Zackheim, H.S., Epstein, Jr., E.H. and Crain, W.R. (1990) "Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients", Journal of the American Academy of Dermatology, 22, 802— 810.
   Google Scholar
• Herrmann, J.J., Roenigk, Jr., H.H., Hurria, A., Kuzel, T.M., Samuelson, E., Rademaker, A.W. and Rosen, S.T. (1995) "Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up", Journal of the American Academy of Dermatology, 33, 234–242.
   Google Scholar
• Powell, F.C., Spiegel, G.T. and Muller, S.A. (1984) "Treatment of parapsoriasis and mycosis fungoides: the role of psoralen and long-wave ultraviolet light A (PUVA)", Mayo Clinic Proceedings, 59, 538— 546.
   Google Scholar
• Scarisbrick, J.J., Child, F.J., Clift, A., Sabroe, R., Whittaker, S.J., Spittle, M. and Russell-Jones, R. (2001) "A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma", British Journal of Dermatology, 144, 1010 — 1015.
   Google Scholar
• Wollina, U., Graefe, T. and Kaatz, M. (2001) "Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up", Journal of Cancer Research and Clinical Oncology, 127, 128–134.
   Google Scholar
• Coors, E.A. and von den Driesch, P. (2000) "Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy", British Journal of Dermatology, 143, 127–131.
   Google Scholar
• Dearden, C., Matutes, E. and Catovsky, D. (2000) "Pentostatin treatment of cutaneous T-cell lymphoma", Oncology ( Williston Park, N.Y.), 14, 37 — 40.
   Google Scholar
• Akpek, G., Koh, H.K., Bogen, S., O'Hara, C. and Foss, F.M. (1999) "Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma", Cancer, 86, 1368–1376.
   Google Scholar
• Fierro, MT., Quaglino, P., Savoia, P., Verrone, A. and Bernengo, M.G. (1998) "Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP", Leukemia Lymphoma, 31, 583— 588.
   Google Scholar
• Greiner, D., Olsen, E.A. and Petroni, G. (1997) "Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lympho-ma", Journal of the American Academy of Dermatology, 36, 950 — 955.
   Google Scholar
• Fierro, MT., Doveil, G.C., Quaglino, P., Savoia, P., Verrone, A. and Bernengo, M.G. (1997) "Combination of etoposide, idarubi-cM, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma", Dermatology, 194, 268 — 272.
   Google Scholar
• Rondelli, D., Lauria, F., Zinzani, P.L., Raspadori, D., Ventura, MA., Galieni, P., et al. (1997) "2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative dis-orders", European Journal of Haematology, 58, 46–50.
   Google Scholar
• Zackheim, H.S., Kashani-Sabet, M. and Hwang, S.T. (1996) "Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients", Journal of the American Academy of Dermatology, 34, 626–631.
   Google Scholar
• Cummings, F.J., Kim, K., Neiman, R.S., Comis, R.L., Oken, MM., Weitzman, S.A., et al. (1991) "Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease", Journal of Clinical Oncology, 9, 565 — 571.
   Google Scholar
• Sorio, R., Tirelli, U., Zagonel, V., Carbone, A. and Monfardini, S. (1990) "Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas", American Journal of Clinical Oncology, 13, 14 — 16.
   Google Scholar
• Kacinski, B.M. and Flick, M. (2001) "Apoptosis and cutaneous T cell lymphoma", Annals of the New York Academy of Sciences, 941, 194— 199.
   Google Scholar
• Szondy, Z., Reichert, U. and Fesus, L. (1998) "Retinoic acids regulate apoptosis of T lymphocytes through an interplay between RAR and RXR receptors", Cell Death and Differentiation, 5, 4 — 10.
   Google Scholar
• Kessler, J.F., Jones, SE., Levine, N., Lynch, P.J., Booth, A.R. and Meyskens, Jr., F.L. (1987) "Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)", Archives of Dermatology, 123, 201–204.
   Google Scholar
• Thomsen, K., Molin, L., Volden, G., Lange Wantzin, G. and Hellbe, L. (1984) "13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group", Acta Dermato-Venereologica, 64, 563 — 566.
   Google Scholar
• Molin, L., Thomsen, K., Volden, G., Aronsson, A., Hammar, H., Hellbe, L., et al. (1987) "Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group", Acta Dermato-Venereologica, 67, 232–236.
   Google Scholar
• Thomsen, K., Hammar, H., Molin, L. and Volden, G. (1989) "Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group", Acta Dermato-Venereologica, 69, 536 — 538.
   Google Scholar
• Zhang, C., Hazarika, P., Ni, X., Weidner, D.A. and Duvic, M. (2002) "Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action", Clinical Cancer Research, 8, 1234 — 1240.
   Google Scholar
• Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, AG., Myskowski, P., et al. (2001) "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lympho-ma: multinational phase II— III trial results", Journal of Clinical Oncology, 19, 2456 — 2471.
   Google Scholar
• Breneman, D., Duvic, M., Kuzel, T., Yocum, R., Truglia, J. and Stevens, V.J. (2002) "Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma", Archives of Dermatology, 138, 325–332.
   Google Scholar
• Querfeld, C., Rosen, S., Guitart, J., Rademaker, A., Fung, B., Posten, W. and Kuzel, T. (2004) "Comparison of selective RAR and RXR retinoid mediated efficacy, tolerance, and survival in refractory cutaneous T-cell lymphoma", Journal of the American Academy of Dermatology. 50, In Press.
   Google Scholar
• Parmar, S. and Platanias, L. (2003) "Interferons: mechanisms of action and clinical applications", Current Opinion in Oncology. 15, 431 — 439.
   Google Scholar
• Bunn, Jr., P.A., Ihde, D.C. and Foon, K.A. (1987) "Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas", International Journal of Cancer Supplement, 1, 9 — 13.
   Google Scholar
• Bunn, Jr., P.A., Ihde, D.C. and Foon, K.A. (1986) "The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas", Cancer, 57, 1689 — 1695.
   Google Scholar
• Kohn, E.C., Steis, R.G., Sausville, E.A., Veach, S.R., Stocker, J.L., Phelps, R., et al. (1990) "Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome", Journal of Clinical Oncology, 8, 155–160.
   Google Scholar
• Vegna, M.L., Papa, G., Defazio, D., Pisani, F., Coppola, G., De Pita, 0., et al. (1990) "Interferon alpha-2a in cutaneous T-cell lymphoma", European Journal of Haematology Supplement, 52, 32–35.
   Google Scholar
• Kaplan, E.H., Rosen, S.T., Norris, D.B., Roenigk, Jr., H.H., Saks, S.R. and Bunn, Jr., P.A. (1990) "Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma", Journal of the National Cancer Institute, 82, 208 — 212.
   Google Scholar
• Stadler, R., Otte, H.G., Luger, T., Henz, B.M., Kuhl, P., Zwingers, T. and Sterry, W. (1998) "Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II", Blood, 92, 3578 — 3581.
   Google Scholar
• Kuzel, T.M., Roenigk, Jr., H.H., Samuelson, E. and Rosen, S.T. (1992) "Suppression of anti-interferon alpha-2a antibody forma-tion in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion", Journal of the National Cancer Institute, 84, 119— 121.
   Google Scholar
• Bukowski, R.M., Tendler, C., Cutler, D., Rose, E., Laughlin, M.M. and Statkevich, P. (2002) "Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation", Cancer, 95, 389 — 396.
   Google Scholar
• Flynn, J.M. and Byrd, J.C. (2000) "Campath-1H monoclonal antibody therapy", Current Opinion in Oncology, 12, 574–581.
   Google Scholar
• Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., et al. (1998) "CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma", Journal of Clinical Oncology, 16, 3257 — 3263.
   Google Scholar
• Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., et al. (2003) "Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome", Blood, 101, 4267–4272.
   Google Scholar
• Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., et al. (2002) "Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)", Blood, 100, 768–773.
   Google Scholar
• Montillo, M., Cafro, A.M., Tedeschi, A., Brando, B., Oreste, P., Veronese, S., et al. (2002) "Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine", Haematologica, 87, 695–700; discussion 700.
   Google Scholar
• Foss, F.M. (2001) "Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma", Annals of the New York Academy of Sciences, 941, 166 — 176.
   Google Scholar
• Hesketh, P., Caguioa, P., Koh, H., Dewey, H., Facada, A., McCaffrey, R., et al. (1993) "Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma", Journal of Clinical Oncology, 11, 1682— 1690.
   Google Scholar
• Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonder-heid, E., et al. (2001) "Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lympho-ma", Journal of Clinical Oncology, 19, 376— 388.
   Google Scholar
• Duvic, M., Kuzel, T.M., Olsen, E.A., Martin, A.G., Foss, F.M., Kim, Y.H., et al. (2002) "Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK(R))", Clinical Lymphoma, 2, 222–228.
   Google Scholar
• Foss, F.M., Bacha, P., Osann, K.E., Demierre, M.F., Bell, T. and Kuzel, T. (2001) "Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication", Clinical Lymphoma, 1, 298 — 302.
   Google Scholar
• Gorgun, G. and Foss, F. (2002) "Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox", Blood, 100, 1399 — 1403.
   Google Scholar
• Shao, R.H., Tian, X., Gorgun, G., Urbano, A.G. and Foss, F.M. (2002) "Arginine butyrate increases the cytotoxicity of DA-B(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene", Leukemia Research, 26, 1077 — 1083.
   Google Scholar
• Knobler, R. and Girardi, M. (2001) "Extracorporeal photoche-moimmunotherapy in cutaneous T cell lymphomas", Annals of the New York Academy of Sciences, 941, 123— 138.
   Google Scholar
• Di Renzo, M., Rubegni, P., De Aloe, G., Paulesu, L., Pasqui, AL., Andreassi, L., et al. (1997) "Extracorporeal photochemotherapy restores Thl/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma", Immunology, 92, 99 — 103.
   Google Scholar
• Edelson, R., Berger, C., Gasparro, F., Jegasothy, B., Heald, P., Wintroub, B., et al. (1987) "Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results", New England Journal of Medicine, 316, 297–303.
   Google Scholar
• Wollina, U., Liebold, K., Kaatz, M., Looks, A., Stuhlert, A. and Lange, D. (2000) "Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemother-apy", Oncology Reports, 7, 1197–1201.
   Google Scholar
• Bisaccia, E., Gonzalez, J., Palangio, M., Schwartz, J. and Klainer, A.S. (2000) "Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution", Journal of the American Academy of Dermatology, 43, 263–271.
   Google Scholar
• Jiang, S.B., Dietz, S.B., Kim, M. and Lim, H.W. (1999) "Extracorporeal photochemotherapy for cutaneous T-cell lym-phoma: a 9.7-year experience", Photodermatology Photoimmunol-ogy & Photomedicine, 15, 161–165.
   Google Scholar
• Zic, J.A., Stricklin, G.P., Greer, J.P., Kinney, MC., Shyr, Y., Wilson, D.C. and King, Jr., L.E. (1996) "Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracor-poreal photochemotherapy", Journal of the American Academy of Dermatology, 35, 935–945.
   Google Scholar
• Prinz, B., Behrens, W., Holzle, E. and Plewig, G. (1995) "Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma — the Dusseldorf and Munich experience", Archives of Dermatological Research, 287, 621–626.
   Google Scholar
• Heald, P., Rook, A., Perez, M., Wintroub, B., Knobler, R., Jegasothy, B., et al. (1992) "Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy", Jour-nal of the American Academy of Dermatology, 27, 427–433.
   Google Scholar
• Suchin, KR., Cucchiara, A.J., Gottleib, S.L., Wolfe, J.T., DeNardo, B.J., Macey, W.H., et al. (2002) "Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution", Archives of Dermatology, 138, 1054–1060.
   Google Scholar
• Haley, RR., Davis, D.A. and Sams, W.M. (1999) "Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis", Journal of the American Academy of Dermatology, 41, 880–883.
   Google Scholar
• Knobler, E., Warmuth, I., Cocco, C., Miller, B. and Mackay, J. (2002) "Extracorporeal photochemotherapy — the Columbia Presbyterian experience", Photodermatology Photoimmunology & Photomedicine, 18, 232–237.
   Google Scholar
• Bigler, RD., Crilley, P., Micaily, B., Brady, LW., Topolsky, D., Bulova, S., et al. (1991) "Autologous bone marrow transplantation for advanced stage mycosis fungoides", Bone Marrow Transplanta-tion, 7, 133–137.
   Google Scholar
• Sterling, J.C., Marcus, R., Burrows, N.P. and Roberts, S.O. (1995) "Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation", Clinical and Experimental Dermatology, 20, 73–75.
   Google Scholar
• Olavarria, E., Child, F., Woolford, A., Whittaker, S.J., Davis, J.G., McDonald, C., et al. (2001) "T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement", British Journal of Haematology, 114, 624–631.
   Google Scholar
• Russell-Jones, R., Child, F., Olavarria, E., Whittaker, S., Spittle, M. and Apperley, J. (2001) "Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival", Annals of the New York Academy of Sciences, 941, 147 — 154.
   Google Scholar
• Koeppel, M.C., Stoppa, A.M., Resbeut, M., Blaise, D., Coignet, M., Coulier, L., et al. (1994) "Mycosis fungoides and allogenic bone marrow transplantation", Acta Dermato-Venereologica, 74, 331— 332.
   Google Scholar
• Rook, A.H., Kubin, M., Fox, F.E., Niu, Z., Cassin, M., Vowels, B.R., et al. (1996) "The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma", Annals of the New York Academy of Sciences, 795, 310 — 318.
   Google Scholar
• Rook, A.H., Zaki, M.H., Wysocka, M., Wood, G.S., Duvic, M., Showe, L.C., et al. (2001) "The role for interleukin-12 therapy of cutaneous T cell lymphoma", Annals of the New York Academy of Sciences, 941, 177 — 184.
   Google Scholar
• Rook, A.H., Wood, G.S., Yoo, E.K., Elenitsas, R., Kao, D.M., Sherman, M.L., et al. (1999) "Interleulcin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses", Blood, 94, 902–908.
   Google Scholar
• Marolleau, J.P., Baccard, M., Flageul, B., Rybojad, M., Laroche, L., Verola, 0., et al. (1995) "High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma", Archives of Dermatol-ogy, 131, 574 — 579.
   Google Scholar
• Baccard, M., Marolleau, J.P. and Rybojad, M. (1997) "Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2", Archives of Dermatology, 133, 656.
   Google Scholar
• Nagatani, T., Kin, S.T., Baba, N., Miyamoto, H., Nakajima, H. and Katoh, Y. (1988) "A case of cutaneous T cell lymphoma treated with recombinant interleulcin 2 (rIL-2)", Acta Dermato-Venereologica, 68, 504— 508.
   Google Scholar
• Koyama, Y., Adachi, M., Sekiya, M., Takekawa, M. and Imai, K. (2000) "Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis", Blood, 96, 1490 — 1495.
   Google Scholar
• Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M.V. and Bates, S.E. (2000) "P21-dependent g(I)arrest with downregulation of cyclin DI and upregulation of cyclin E by the histone deacetylase inhibitor FR901228", British Journal of Cancer, 83, 817–825.
   Google Scholar
• Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H., Dahmoush, L., et al. (2001) "Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report", Blood, 98, 2865–2868.
   Google Scholar
• Marshall, J.L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M.H., et al. (2002) "A phase I trial of depsipeptide (FR901228) in patients with advanced cancer", Journal of Experimental Ther-apeutics & Oncology, 2, 325–332.
   Google Scholar
• Sandor, V., Bakke, S., Robey, R.W., Kang, M.H., Blagosklonny, M.V., Bender, J., et al. (2002) "Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms", Clinical Cancer Research, 8, 718 —728.
   Google Scholar
• Muche, J.M. and Sterry, W. (2002) "Vaccination therapy for cutaneous T-cell lymphoma", Clinical and Experimental Dermatol-ogy, 27, 602–607.
   Google Scholar
• Chatterjee, M., Mrozek, E., Vaickus, L., Oseroff, A., Stoll, H., Russell, D., et al. (1993) "Antiidiotype (Ab2) vaccine therapy for cutaneous T-cell lymphoma", Annals of the New York Academy of Sciences, 690, 376–377.
   Google Scholar
• Jakob, T., Walker, P.S., Krieg, A.M., von Stebut, E., Udey, M.C. and Vogel, J.C. (1999) "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Thl responses", International Archives of Allergy and Immunology, 118, 457–461.
   Google Scholar
• Jakob, T., Walker, P.S., Krieg, A.M., Udey, M.C. and Vogel, J.C. (1998) "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmenta-tion of Th 1 responses by immunostimulatory DNA", Journal of Immunology, 161, 3042–3049.
   Google Scholar
• Vonderheid, E.C., Thompson, R., Smiles, K.A. and Lattanand, A. (1987) "Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy", Archives of Dermatology, 123, 757–763.
   Google Scholar
• Dreno, B., Claudy, A., Meynadier, J., Verret, J.L., Souteyrand, P., Ortonne, J.P., et al. (1991) "The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate", British Journal of Dermatology, 125, 456–459.
   Google Scholar
• Nicolas, J.F., Balblanc, J.C., Frappaz, A., Chouvet, B., Delcombel, M. and Thivolet, J. (1989) "Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a", Dermatologica, 179, 34— 37.
   Google Scholar
• Thestrup-Pedersen, K., Hammer, R., Kaltoft, K., Sogaard, H. and Zachariae, H. (1988) "Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate", British Journal of Dermatology, 118, 811 —818.
   Google Scholar
• Aviles, A., Guzman, R., Garcia, E.L. and Diaz-Maqueo, J.C. (1996) "Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma", Cancer Biotherapy & Radiopharmaceuticals, 11, 21–24.
   Google Scholar
• Kuzel, T.M., Roenigk, Jr., H.H., Samuelson, E., Herrmann, ii., Hurria, A., Rademaker, A.W. and Rosen, S.T. (1995) "Effective-ness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome", Journal of Clinical Oncology, 13, 257 — 263.
   Google Scholar
• Roenigk, Jr., H.H., Kuzel, T.M., Skoutelis, A.P., Springer, E., Yu, G., Caro, W., et al. (1990) "Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma", The Journal of Investigative Dermatology, 95, 198S–205S.
   Google Scholar
• Stadler, R. and Otte, H.G. (1995) "Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photo-chemotherapy", Recent Results Cancer Res, 139, 391 — 401.
   Google Scholar
• Rupoli, S., Barulli, S., Guiducci, B., Offidani, M., Mozzicafreddo, G., Simonacci, M., et al. (1999) "Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group", Haematologica, 84, 809 — 813.
   Google Scholar
• Chiarion-Sileni, V., Bononi, A., Fornasa, CV., Soraru, M., Alaibac, M., Ferrazzi, E., et al. (2002) "Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma", Cancer, 95, 569 — 575.
   Google Scholar
• Foss, F.M., Ihde, D.C., Linnoila, I.R., Fischmann, A.B., Schechter, G.P., Cotelingam, J.D., et al. (1994) "Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome", Journal of Clinical Oncology, 12, 2051 —2059.
   Google Scholar
• Soligo, D., Ibatici, A., Berti, E., Morandi, P., Longhi, E., Venegoni, L., et al. (2003) "Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmye-loablative regimen", Bone Marrow Transplantation, 31, 663–666.
   Google Scholar
• Guitart, J., Wickless, S.C., Oyama, Y., Kuzel, T.M., Rosen, S.T., Traynor, A. and Burt, R. (2002) "Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma", Archives of Dermatology, 138, 1359 —1365.
   Google Scholar
• Masood, N., Russell, K.J., Olerud, J.E., Sabath, D.E., Sale, G.E., Doney, K.C., et al. (2002) "Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation", Journal of the American Academy of Dermatology, 47, 140–145.
   Google Scholar
• Molina, A., Zain, J., Arber, D.A., Angelopoulou, M., O'Donnell, MR., Parker, P., et al. (2003) "Is Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Potentially Curative in a Group of Refractory Cutaneous T-Cell Lymphomas (CTCLs)? Durable Clinical, Cytogenic and Molecular Remissions after AHSCT for Refractory Sezary Syndrome and Mycosis Fungoides". Blood, 102, Abstract #1737.
   Google Scholar